{"database": "openregs", "table": "dockets", "rows": [["FDA-2026-P-6789", "FDA", "Requests that the FDA review whether the two primary generic bicalutamide tablet suppliers can assure the safety, efficacy, and quality of bicalutamide tablets for the intended prostate cancer patient population.", "Nonrulemaking", "2026-06-15T20:58:01Z", "0b000064b93304e5"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2026-P-6789"], "units": {}, "query_ms": 0.2086220047203824, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}